In terms of combination of immunotherapy, the CD47 antibody that focuses on re‐education of TA‐MG and TA‐MAC needs to be combined with other immunotherapy such as dendritic vaccines and adoptive T‐cell therapy to treat gliomas. Here, CD47 is linked to central nervous system cancer.